Systemic treatment of non-small cell lung cancer brain metastases

Systemic treatment of non-small cell lung cancer brain metastases

In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib o...

Full description

Bibliographic Details
Main Authors: Ida Cedrych, Maksymilian A. Kruczała, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Marian Reinfuss
Format: Article
Language:English
Published: Termedia Publishing House 2016-12-01
Series:Contemporary Oncology
Subjects:
breast cancer
brain metastases
systemic therapy
targeted therapy
Online Access:https://www.termedia.pl/Systemic-treatment-of-non-small-cell-lung-cancer-brain-metastases,3,28896,1,1.html

Internet

https://www.termedia.pl/Systemic-treatment-of-non-small-cell-lung-cancer-brain-metastases,3,28896,1,1.html

Similar Items